

stakeholder perceptions, experiences, and expectations; provide an early warning of issues with the service; or focus attention on areas where communication, training, or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative, and actionable communications between ONC and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management.

The solicitation of feedback will target areas such as timeliness, appropriateness, accuracy of information, courtesy, efficiency of service delivery, and resolution of issues with service delivery. If this information is not collected, vital feedback from TEFCA users and stakeholders on the ONC services will be unavailable.

Likely respondents to the data collections under this generic clearance will be the Qualified Health Information Networks® (QHINs™), which are health

information networks approved to access and exchange data through TEFCA. Over each of the next three years, an estimated 15 respondents are expected to participate, with approximately 7 qualitative feedback activities occurring annually and an average of 71 responses per respondent. The frequency of response will vary by activity, with each response taking an average of 80 minutes. This results in a total estimated burden of 1,420 hours annually, or 4,260 hours over the three-year period.

ESTIMATED ANNUALIZED BURDEN HOUR TABLE

| Type of respondent | Form name                                     | Number of respondents | Number responses per respondent | Average burden per response (in hours) | Total burden hours |
|--------------------|---|-----------------------|---------------------------------|--|--------------------|
| QHIN .....         | QHIN Application .....                        | 15                    | 1                               | 3                                      | 45                 |
| QHIN .....         | QHIN Monthly Report .....                     | 15                    | 12                              | 2                                      | 360                |
| QHIN .....         | QHIN Quarterly Report .....                   | 15                    | 4                               | 2                                      | 120                |
| QHIN .....         | QHIN Attestation .....                        | 15                    | 1                               | 1                                      | 15                 |
| QHIN .....         | TEFCA Directory Submission (weekly) .....     | 15                    | 1040                            | 0.033                                  | 520                |
| QHIN .....         | Program Evaluation or Usability Testing ..... | 15                    | 4                               | 4                                      | 240                |
| QHIN .....         | Other .....                                   | 15                    | 4                               | 2                                      | 120                |
| <b>Total .....</b> | .....   | .....                 | .....                           | .....                                  | <b>1,420</b>       |

**Catherine Howard,**  
*Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.*  
 [FR Doc. 2026-09285 Filed 5-8-26; 8:45 am]  
**BILLING CODE 4150-45-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Eye Institute; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Eye Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<https://videocast.nih.gov>).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The intramural programs

and projects and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Eye Council.

*Date:* June 5, 2026.

*Open:* 9:00 a.m. to 10:30 a.m.

*Agenda:* Presentation of the NEI Director’s report, discussion of NEI programs, and concept clearances.

*Address:* National Eye Institute, 6700B Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Closed:* 10:30 a.m. to 11:00 a.m.

*Agenda:* To review and evaluate personnel qualifications and performance, and competence of individual investigators.

*Address:* National Eye Institute, 6700B Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Hyo-Jung Anna Han, Acting Director Division of Extramural Activities, National Eye Institute, 6700B Rockledge Drive, Bethesda, MD 20892, [anna.han@nih.gov](mailto:anna.han@nih.gov).

Registration is not required to attend the open portion of this meeting.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice before the meeting or within 15 days after the meeting. The statement should include the name, address, telephone number and when applicable, the business or

professional affiliation of the interested person.

Information is also available on the Institute’s/Center’s home page: <https://www.nei.nih.gov/about/advisory-committees/national-advisory-eye-council-naec>, where an agenda and any additional information for the meeting will be posted when available.

Dated: May 6, 2026.

**Rosalind M. Niamke,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-09228 Filed 5-8-26; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of

cancer, infectious diseases, and autoimmune diseases.

**FOR FURTHER INFORMATION CONTACT:**

Inquiries related to this license opportunity should be directed to: Nikki Guyton, Ph.D., Unit Supervisor, NCI, Technology Transfer Center, Email: [darackn@mail.nih.gov](mailto:darackn@mail.nih.gov) or Phone: 240–276–5493.

**SUPPLEMENTARY INFORMATION:** Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods of cellular immunotherapy.

T cells constitutively express inhibitory molecules that limit the activation response to antigens by the T cell antigen receptor (TCR). Among these are the transmembrane adapter proteins SIT1, LAX 1 and TRA T1. These appear to tonically associate with the TCR and inhibit signal transduction. Researchers at the NICHD have identified SIT1, LAX 1 and TRA T1 as potential targets for T-cell immunotherapy. Mouse models have demonstrated that deletion of SIT1, LAX1 and TRA T1—or expression of nonfunctional mutant versions of these proteins in mouse T cells—enhances TCR signaling and significantly increases T cell cytotoxicity against tumor cells. Experiments confirming these results in human T cells are currently underway. This discovery provides a new therapeutic approach to greatly improve clinical outcomes of T-cell immunotherapy in treating cancers. It also holds potential to treat infectious diseases or autoimmune diseases.

This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 and the intellectual property rights have been assigned to the Government of the United States of America.

*NIH Reference Number:* E–004–2024.

*Product Type:* Therapeutic.

*Therapeutic Area(s):* Oncology | Immunology.

*Potential Commercial Applications:*

- Treatment for cancer.
- Treatment for infectious diseases.
- Treatment for autoimmune diseases.

*Competitive Advantages:*

- Potentially superior therapeutic benefit in cancer by:
  - Enhancing tumoricidal activity of T-cell immunotherapy.
  - Overcoming immunosuppression in the tumor microenvironment.
- Potentially superior therapeutic benefit in infectious diseases by enhancing immune responses to pathogens.

- Potentially superior therapeutic benefit in autoimmune disease by enhancing the generation or function of antigen-specific regulator T cells (Tregs).

*Patent Status:* A PCT application was filed on January 24, 2025.

*Development Stage:* Pre-clinical (in vivo validation).

*Collaboration Opportunity:* Researchers at the NICHD seek licensing for further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.

Dated: May 6, 2026.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2026–09292 Filed 5–8–26; 8:45 am]

**BILLING CODE 4167–05–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Social and Community Influences on Health Integrated Review Group; Health Promotion in Communities Study Section.

*Date:* June 9–10, 2026.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Helena Eryam Dagadu, MPH, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3137 Bethesda, MD 20892, (301) 435–1266 [dagaduhe@csr.nih.gov](mailto:dagaduhe@csr.nih.gov).

*Name of Committee:* Population Sciences and Epidemiology Integrated Review Group; Lifestyle and Health Behaviors Study Section.

*Date:* June 10, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Jewel L. Wright, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, (301) 827–9038 [jewel.wright@nih.gov](mailto:jewel.wright@nih.gov).

*Name of Committee:* Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Maximizing Investigators' Research Award—E Study Section.

*Date:* June 11–12, 2026.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Vandana Kumari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–3290 [vandana.kumari@nih.gov](mailto:vandana.kumari@nih.gov).

*Name of Committee:* Infectious Diseases and Immunology A Integrated Review Group; Molecular and Cellular Biology of Virus Infection Study Section.

*Date:* June 11, 2026.

*Time:* 10:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Syed Mohammad Moin, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 594–7593 [syed.moin@nih.gov](mailto:syed.moin@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Infectious Disease Drug Development and Molecular Pharmacology.

*Date:* June 11, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Ekaterina Mikhailovna Nestorovich, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827–1367 [ekaterina.nestorovich@nih.gov](mailto:ekaterina.nestorovich@nih.gov).

*Name of Committee:* Infectious Diseases and Immunology B Integrated Review Group; Viral Dynamics and Transmission Study Section.

*Date:* June 11, 2026.

*Time:* 10:00 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.